新股消息 | 麦科田拟港股上市 中国证监会要求补充说明公司辅导备案情况等

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested Shenzhen Maikedian Biomedical Technology Co., Ltd. to provide supplementary information regarding its overseas listing application and A-share listing plans, highlighting the need for legal verification of various operational and financial aspects [1][2][3]. Group 1 - The CSRC has asked Maikedian to clarify its capital increase, decrease, and share transfer pricing, including whether there are any unfulfilled capital contributions or issues with the capital contribution methods [1][2]. - The company must provide details on its subsidiaries' business scope, including e-commerce, medical research, and testing services, and confirm whether it has obtained necessary qualifications and licenses [1][3]. - Maikedian is required to confirm compliance with the regulations regarding overseas issuance and listing, particularly if there are any prohibitive circumstances [1][2]. Group 2 - The company must disclose information about its major shareholders, particularly foreign and Hong Kong investors, to ensure compliance with legal restrictions on shareholding [2]. - The progress of state-owned shareholders in fulfilling state asset management procedures must be reported [2]. - The company needs to clarify the shareholding structure before and after the full exercise of the over-allotment option, particularly regarding the proportion of domestic and H-shares [3]. Group 3 - Maikedian's product portfolio includes over 50 life support products, 80 minimally invasive intervention products, and 210 in vitro diagnostic products, which are commercialized and meet various clinical needs [3]. - The company's products are distributed in over 140 countries and regions globally, with coverage in more than 6,000 hospitals in China, including approximately 90% of top-tier hospitals [3].